289 related articles for article (PubMed ID: 8174806)
1. Considerations in performing virus spiking experiments and process validation studies.
Darling AJ
Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
[TBL] [Abstract][Full Text] [Related]
2. Criteria for the choice of viruses in validation studies.
Minor PD
Dev Biol Stand; 1993; 81():215-9. PubMed ID: 8174805
[TBL] [Abstract][Full Text] [Related]
3. Process changes and their effect on process evaluation for viral clearance.
Marcus-Sekura C
Dev Biol Stand; 1996; 88():125-30. PubMed ID: 9119123
[TBL] [Abstract][Full Text] [Related]
4. At what stage should virus inactivation be carried out?
Dorner F; Barrett PN; Eibl J
Dev Biol Stand; 1993; 81():137-43. PubMed ID: 8174796
[TBL] [Abstract][Full Text] [Related]
5. Theoretical and technical concerns in inactivation/elimination of viruses in plasma derivatives.
Hilfenhaus J; Niedrig M; Nowak T
Dev Biol Stand; 1993; 81():117-23. PubMed ID: 8174794
[TBL] [Abstract][Full Text] [Related]
6. Process scale considerations in evaluation studies and scale-up.
Walter JK; Werz W; Berthold W
Dev Biol Stand; 1996; 88():99-108. PubMed ID: 9119169
[TBL] [Abstract][Full Text] [Related]
7. Theoretical considerations on viral inactivation or elimination.
Willkommen H; Löwer J
Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
[No Abstract] [Full Text] [Related]
8. Viral safety evaluation of plasma-derived therapeutic products.
Farshid M
Dev Biol (Basel); 2004; 118():11-5. PubMed ID: 15645668
[TBL] [Abstract][Full Text] [Related]
9. Chromatographic removal of viruses from plasma derivatives.
Burnouf T
Dev Biol Stand; 1993; 81():199-209. PubMed ID: 8174804
[TBL] [Abstract][Full Text] [Related]
10. Viral safety of solvent-detergent treated blood products.
Horowitz B; Prince AM; Horowitz MS; Watklevicz C
Dev Biol Stand; 1993; 81():147-61. PubMed ID: 8174797
[TBL] [Abstract][Full Text] [Related]
11. Validation of purification procedures for removing and/or inactivating viruses in biologicals: points to consider.
Vicari G
Dev Biol Stand; 1991; 75():227-32. PubMed ID: 1794625
[TBL] [Abstract][Full Text] [Related]
12. Viral validation of the manufacturing process of high purity albumin from placentas.
Grandgeorge M; Véron JL
Dev Biol Stand; 1993; 81():237-44. PubMed ID: 8174808
[TBL] [Abstract][Full Text] [Related]
13. Viral validation design of a manufacturing process.
Larzul D
Dev Biol Stand; 1999; 99():139-50. PubMed ID: 10404885
[TBL] [Abstract][Full Text] [Related]
14. Affinity chromatography to remove viruses during preparation of plasma derivatives.
Lawrence JE
Dev Biol Stand; 1993; 81():191-7. PubMed ID: 8174803
[TBL] [Abstract][Full Text] [Related]
15. Viral safety evaluation of biopharmaceuticals and homoeopathic preparations of human or animal origin.
Immelmann A
Pharmeur Sci Notes; 2006 Aug; 2006(1):41-5. PubMed ID: 17694646
[TBL] [Abstract][Full Text] [Related]
16. Relationship between nature and source of risk and process validation.
Berthold W; Werz W; Walter JK
Dev Biol Stand; 1996; 88():59-71. PubMed ID: 9119164
[No Abstract] [Full Text] [Related]
17. Virological issues in the use of cell therapies.
Minor PD
Dev Biol (Basel); 2004; 118():151-3. PubMed ID: 15645685
[TBL] [Abstract][Full Text] [Related]
18. Use of bacteriophages as surrogates for mammalian viruses.
McAlister M; Aranha H; Larson R
Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
[TBL] [Abstract][Full Text] [Related]
19. [Viral safety concept: application to blood and blood products].
Trouvin JH
Rev Prat; 2005 Nov; 55(18):2033-8. PubMed ID: 16419908
[TBL] [Abstract][Full Text] [Related]
20. Methodological aspects of the validation of purification procedures of human/animal-derived products to remove unconventional slow viruses.
Pocchiari M
Dev Biol Stand; 1991; 75():87-95. PubMed ID: 1794633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
